*Department of Clinical Pharmacy, Institute of Pharmacy, University of Hamburg, Hamburg, Germany; and

†Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free Hospital, London, United Kingdom.

Correspondence: Sebastian G. Wicha, PhD, Department of Clinical Pharmacy, Institute of Pharmacy, University of Hamburg, Bundesstrasse 45, 20146 Hamburg, Germany (e-mail: [email protected]).

P. Chowdary has received honoraria from Bayer, CSL Behring, Freeline, Novo Nordisk, Pfizer, SOBI, and Takeda. P. Chowdary is currently receiving a grant (Grant Reference #53232605) from Pfizer Limited and has served on advisory boards for Bayer, Boehringer Ingelheim, CSL Behring, Chugai, Freeline, Novo Nordisk, Pfizer, Roche, Sanofi, Spark, Sobi, and Takeda. For the remaining authors, none were declared.

D. W. Uster and S. G. Wicha performed the analyses and wrote the manuscript; S. G. Wicha designed the study; P. Chowdary developed the idea, designed the data collection, and critically reviewed the manuscript; and A. Riddell, C. Garcia, E. Aradom, and M. Musarara collected the clinical data and critically revised the manuscript. All the authors have approved the manuscript.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.drug-monitoring.com).